KUPPUSAMY KARTHIK, Senior Vice President of Clinical Solutions, has demonstrated a clear pattern of insider activity focused exclusively on shares of Quest Diagnostics Incorporated (DGX), as evidenced by SEC Form 4 filings. Over 26 transactions, Karthik’s activity reveals a net selling bias, with total sell transactions amounting to $3,027,454.54 compared to total buy transactions of $2,393,296.90. Notably, Karthik has not engaged in any recent purchases, with all five of the most recent transactions involving sales or dispositions of DGX shares. These include a significant sale on March 4, 2026, valued at $538,372.08, and earlier transactions such as a $375,700 sale on July 31, 2025, and a $874,497.60 sale on July 30, 2025. Smaller transactions, such as those involving the exercise of options or the acquisition of shares through awards, are also present but are overshadowed by the larger sell-offs.
The data highlights Karthik’s consistent focus on DGX, with no diversification into other companies. While some transactions involve the acquisition of shares through awards or options exercises, such as a $127,0132 award on March 4, 2026, the overall trend leans heavily toward reducing holdings. This pattern aligns with a broader strategy of monetizing equity positions, particularly in recent years. The absence of purchases since at least 2024 underscores this directional shift. Karthik’s activity provides a transparent view of insider behavior within Quest Diagnostics, reflecting a measured approach to equity management over time.
AI-assisted summary